Skip to main content
. 2021 Sep 22;14:4901–4913. doi: 10.2147/JIR.S329401

Figure 4.

Figure 4

Effects of HH-N25 on hormonal signaling in breast cancer. Dose-dependent plot of the effects of HH-N25 on (A) the progesterone receptor (PR), (B) androgen receptor (AR), and (C) mineralocorticoid receptor (MR) signaling pathways in the absence (upper panel) and presence of the respective receptors. (D) Docking profiles of HH-N25 with the (D) progesterone receptor and (E) androgen receptor.